Published in Nature on June 05, 2003
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov (2012) 2.57
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res (2011) 1.92
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Angiogenesis in cancer. Vasc Health Risk Manag (2006) 1.49
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol (2005) 1.34
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol (2012) 1.30
MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett (2012) 1.22
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A (2011) 1.16
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol (2011) 1.10
Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res (2009) 1.07
High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area. Pharm Res (2014) 1.03
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther (2008) 0.96
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst (2015) 0.95
Radionuclide carriers for targeting of cancer. Int J Nanomedicine (2008) 0.94
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast (2009) 0.91
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol (2015) 0.89
Oxygen-mediated endocytosis in cancer. J Cell Mol Med (2010) 0.84
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol (1985) (2013) 0.82
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast. Oncotarget (2015) 0.82
Capsaicin-induced activation of p53-SMAR1 auto-regulatory loop down-regulates VEGF in non-small cell lung cancer to restrain angiogenesis. PLoS One (2014) 0.80
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs (2010) 0.79
Tumorigenesis: cell defense against hypoxia? Oncol Rev (2013) 0.77
Hypoxic stress, hepatocytes and CACO-2 viability and susceptibility to Shigella flexneri invasion. Rev Inst Med Trop Sao Paulo (2013) 0.77
Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol (2016) 0.75
Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Med (2013) 0.75
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Laser-capture microdissection. Nat Protoc (2006) 3.80
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol (2004) 1.81
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Anoikis: cancer and the homeless cell. Nature (2004) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur Urol (2008) 1.48
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.45
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Laser capture microdissection technology. Expert Rev Mol Diagn (2007) 1.43
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic (2002) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 1.32
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 1.31
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res (2005) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Ovarian cancer detection by logical analysis of proteomic data. Proteomics (2004) 1.28
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28
Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem (2006) 1.28
The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A (2006) 1.27
Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia (2002) 1.26
Biomarker amplification by serum carrier protein binding. Dis Markers (2004) 1.26
An initial characterization of the serum phosphoproteome. J Proteome Res (2009) 1.26
Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) (2005) 1.25
Clinical proteomics and biomarker discovery. Ann N Y Acad Sci (2004) 1.24
Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol (2010) 1.23
Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One (2009) 1.23
Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol (2006) 1.23
c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res (2006) 1.22
Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol (2004) 1.20
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 1.18
Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res (2004) 1.17
Cancer's deadly signature. Nat Genet (2003) 1.16
Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn Mol Pathol (2004) 1.16
A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res (2004) 1.16
Laser capture microdissection. Methods Mol Biol (2006) 1.12
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs (2006) 1.11
Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc (2011) 1.11
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol (2007) 1.10
Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest (2010) 1.09
Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn (2007) 1.09
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer (2007) 1.08
CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics (2005) 1.08
Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl (2009) 1.08
Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug Chem (2005) 1.07
Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano Res (2008) 1.07
Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res (2011) 1.07
Pathology of the future: molecular profiling for targeted therapy. Cancer Invest (2005) 1.06
Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci U S A (2003) 1.06
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics (2004) 1.05
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res (2003) 1.04
Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods (2004) 1.03
Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn (2002) 1.03
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res (2005) 1.03
Hereditary papillary renal carcinoma type I. Curr Mol Med (2004) 1.03
One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One (2011) 1.03
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01
Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. Urol Oncol (2004) 1.01
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther (2006) 1.00
Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics (2004) 1.00
Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev (2002) 1.00
Clinical applications of proteomics. J Nutr (2003) 0.99